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INTRODUCTION
Hepatitis B virus (HBV) infects more than 350 million
people worldwide and is one of the major causes of chronic
liver disease in Asia-Pacific region. Chronic HBV carriers man-
ifest variable stages of liver inflammation and fibrosis in both
clinical and pathologic aspects. The most serious outcome of
those is cirrhosis that is not only a major cause of liver related
death but also a main risk factor of hepatocellular carcinoma
(HCC) in chronic HBV carriers. Therefore, the objectives of
many basic researches and antiviral drugs for HBV were to
prevent or retard the progression of cirrhosis. Among chronic
HBV carriers, there are individual differences in the progres-
sion of cirrhosis. Even some of them never progress to cirrho-
sis. However, very few studies have assessed the progression
rate of fibrosis or cirrhosis in chronic HBV carriers because
of complex pathogenesis and the requirement of long term
observation. 
Several individual gene differences influence the progres-
sion rate of fibrosis. One of those is a cytokine gene polymor-
phism that influences the production or the activation of cy-
tokines, linked to inflammation and fibrosis.
Transforming growth factor (TGF)-b is a multifunctional
cytokine that regulates variety of cellular processes includ-
ing proliferation, differentiation, apoptosis, angiogenesis and
wound healing related to produce extracellular matrix. There
are three isoforms of TGF-b (TGF-b1, -b2, and -b3) that are
encoded by distinct genes, but have similar biologic actions
(1). Of these, TGF-b1 is a major cytokine that contributes to
liver fibrosis via activating hepatic stellate cells and increas-
ing the synthesis of extracellular matrix (2).
Seven genetic polymorphisms of TGF-b1 have been iden-
tified: 3 in the upstream region of the gene at positions -988,
-800, and -509; 1 in a nontranslated region at position +72;
2 in the signal peptide sequence region at codon 10 (position
+869 C or T) and 25 (position +915 G or C); and 1 in the pro-
tein coding region at codon 629 (3). TGF-b1 gene polymor-
phisms at codon 10 and 25 affect the amounts of TGF-b1 pro-
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Influence of Transforming Growth Factor-b1 Gene Polymorphism 
at Codon 10 on the Development of Cirrhosis in Chronic Hepatitis 
B Virus Carriers
Transforming growth factor (TGF)-b1 is a key cytokine producing extracellular matrix.
We evaluated the effect of TGF-b1 gene polymorphism at codon 10 on the devel-
opment of cirrhosis in patients with chronic hepatitis B. One hundred seventy eight
patients with chronic hepatitis (CH, n=57) or liver cirrhosis (LC, n=121), who had
HBsAg and were over 50 yr old, were enrolled. The genotypes were determined
by single strand conformation polymorphism. There were no significant differences
in age and sex ratio between CH and LC groups. HBeAg positivity and detection
rate of HBV DNA were higher in LC than in CH groups (P=0.055 and P=0.003, res-
pectively). There were three types of TGF-b1 gene polymorphism at codon 10: pro-
line homozygous (P/P), proline/leucine heterozygous (P/L), and leucine homozy-
gous (L/L) genotype. In CH group, the proportions of P/P, P/L, and L/L genotype
were 32%, 51%, and 17%, respectively. In LC group, the proportions of those geno-
types were 20%, 47%, and 33%, respectively. The L/L genotype was presented
more frequently in LC than in CH groups (P=0.017). Multivariate logistic regression
analysis confirms that detectable HBV DNA (odds ratio [OR]: 3.037, 95% confidence
interval [CI]: 1.504-6.133, P=0.002) and L/L genotype (OR: 3.408, 95% CI: 1.279-
9.085, P=0.014) are risk factors for cirrhosis.
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duction in vivo and in vitro. In the lungs, leucine homozy-
gous genotype (L/L, +869 T/T) at codon 10 was associated
with increased serum level of TGF-b1 and lung fibrosis (4).
Arginine homozygous genotype (+915 G/G) at codon 25
was associated with in vitro increased leukocyte production
of TGF-b1 and lung fibrosis (4). In the liver, arginine homozy-
gous genotype at codon 25 was associated with liver fibrosis
(5). However, genetic polymorphism at codon 10 showed con-
flicting results as to which genotype was more fibrogenic in
the liver (5-9). These conflicting results could be attributed
to the complex pathogenesis and various factors that contribute
to liver fibrosis. 
There has been no genetic polymorphism at codon 25 in
Koreans (10). Present study investigated whether the genet-
ic polymorphism at codon 10 is associated with the develop-
ment of cirrhosis in chronic HBV carriers. 
MATERIALS AND METHODS
Patients
Two hundred and twenty Korean patients with cirrhosis
(including HCC with underlying cirrhosis), who had hep-
atitis B surface antigen (HBsAg, RIA, Abbott Laboratory,
Chicago, IL, USA) for over 6 months and no hepatitis C virus
antibody (anti-HCV, RIA, General Biologicals Corp, Hsin
Chu, Taiwan), were admitted to Gil Hospital, Incheon, Korea
from January 2001 to January 2005. Among those, one hun-
dred and twenty-one patients who had alcohol intake of less
than 20 g/day and were over 50 yr old were assigned to liver
cirrhosis (LC) group. Eighteen patients in LC group were ad-
mitted due to non liver related symptoms and diseases. The
other 103 patients visited hospital due to liver related symp-
toms. Diagnosis of cirrhosis was based on at least 2 of the fol-
lowings: 1) gastroesophageal varices on endoscopy, 2) cirrhot-
ic surface or regenerating nodules of liver and 3) splenomegaly
by radiologic images (ultrasonography or computed tomog-
raphy). 
Eighty-four Korean chronic hepatitis B patients, who had
HBsAg for over 6 months, no anti-HCV, no clinical signs of
cirrhosis (above criteria), alcohol intake of less than 20 g/day
and were over 50 yr old, were admitted to the same hospital
during the same periods. Among these, 9 patients were exclud-
ed because they had history of antiviral treatment for over one
year. Eighteen patients were also excluded because their pla-
telet counts were less than 150,000/mL. Therefore, 57 chron-
ic hepatitis B patients were enrolled and assigned to chronic
hepatitis (CH) group. In CH group, 17 patients were admit-
ted due to liver related symptoms. Twenty-five patients vis-
ited the hospital due to non liver related diseases and symp-
toms. Fifteen patients were incidentally diagnosed as chron-
ic hepatitis B by National health examination. 
Determination of clinical and laboratory parameters
All patients’ laboratory data including hepatitis B e anti-
gen (HBeAg, RIA, Dainabot Co., Tokyo, Japan) and the level
of HBV DNA (Diagene Inc., Basel, Switzerland) were col-
lected within 6 months at enrollment. However, if patients
were using antiviral agents, those data before antiviral treat-
ment were taken for analysis. Whole blood samples were col-
lected and stored at -70℃refrigerator for genetic assay.
All patients gave informed consents for blood sampling
and using personal data. The study protocol was approved
by institutional review board of Gil Hospital, Incheon, Korea
and in accordance with the Helsinki Declaration.
Genetic polymorphism at codon 10 in TGF-b1
Genomic DNAs were extracted from peripheral blood leu-
kocytes using proteinase K and phenol/chloroform. Polyme-
rase chain reaction (PCR) was performed by using a primer
set (sense 5′ -TGT TCG CGC TCT CGG CAG T-3′ , anti-
sense 5′ -TCA CCA GCT CCA TGT CGA TA-3′ ) that ampli-
fied the DNA fragment including codon 10. PCR mixture
consisted of MgCl2 1.5 mM/L, KCl 50 mM/L, Tris-HCl 10
mM/L, dNTP 200 M/L, primer 0.5 mM/L, Taq polymerase
1 U (Bioneer, Daejeon, Korea), and genomic DNA 50 ng.
After initial denaturation at 94℃ for 5 min, thermocycling
consisted of denaturation at 94℃for 30 sec, annealing at 60℃
for 30 sec, extension at 72℃for 30 sec for 35 cycles, and fol-
lowed by a final extension at 72℃for 5 min. 
For the single stranded conformational polymorphism
(SSCP) analysis, 2 mL of the PCR product were mixed with
8 mL of denaturing solution containing formamide, 250 mM
NaOH, 25 mM EDTA, and 0.05% bromophenol blue. Then
the DNA samples were denatured at 94℃for 5 min, dipped
in ice and loaded onto a 13.5% polyacrylamide (acrylamide
to bisacrylamide ratio of 29:1) gel. Single-stranded DNA
migrated through the gel at 40 W power for 6 hr in a 4℃
cold room and visualized by silver staining. 
To define the genotyping results, selected above PCR-am-
plified DNA samples (n=10, respectively, for each SSCP pat-
terns) were examined by DNA sequencing.
Statistical analysis
Continuous variables were expressed as mean æstandard
deviation. The Student t-test and chi-square-test were used
to compare variables between LC and CH groups. The con-
sistency of genotype frequencies with Hardy-Weinberg equi-
librium was checked. The multivariate logistic regression anal-
ysis was used for identifying independent risk factors of the
development of cirrhosis. A P value less than 0.1 in univari-
ate analysis and 0.05 in multivariate analysis were considered
statistically significant. The SPSS version 10.0 (SPSS, Chica-
go, IL, USA) was used for statistical analysis.566 S.K. Yu, O.S. Kwon, H.S. Jung, et al.
RESULTS
Clinical characteristics of LC and CH groups
As shown in Table 1, mean age and sex ratio were not dif-
ferent between LC and CH groups. The LC group showed
abnormal laboratory features of deteriorated liver functions
and portal hypertension such as low albumin level, high total
bilirubin level, low platelet count, and prolonged prothrom-
bin time. In contrast, the CH group had minor laboratory
abnormalities in those features. HCC was present in 70 pati-
ents in LC group, but absent in CH group. The HBeAg pos-
itivity and the detection rate of HBV DNA by hybridiza-
tion capture method were higher in LC than in CH group
(P=0.055 and P=0.003, respectively).
Distribution of genotypes at codon 10 in TGF-b1
The SSCP results according to TGF-b1 gene polymorphism
at codon 10 showed 3 different patterns (Fig. 1). The 2 bands,
3 bands, and 1 band represented proline homozygous (P/P)
genotype, heterozygous (P/L) genotype, and leucine homozy-
gous (L/L) genotype, respectively. These genotypes were con-
firmed by direct DNA sequencing as previously mentioned.
The distributions of genotype at codon 10 in LC and CH
groups are shown in Fig. 2. In CH group, the proportions
of P/P, P/L, and L/L genotypes were 32%, 51%, and 17%,
respectively. In LC group, the proportions of P/P, P/L, and
L/L genotypes were 20%, 47%, and 33%, respectively. The
proportion of P/L genotype was similar between both study
groups. The proportion of P/P genotype was higher than that
of L/L genotype in CH group, whereas the proportion of L/L
genotype was higher than that of P/P genotype in LC group.
When the proportions of P/P and L/L genotypes were com-
pared between both study groups, the proportion of L/L geno-
type was higher in LC than in CH group (P=0.017). Con-
versely, the proportion of P/P genotype was higher in CH
than in LC group (P=0.017). If cirrhotic patients without
HCC (n=51) were selected in LC group, the proportions of
P/P, P/L, and LL genotypes were 18%, 41%, and 41%, res-
pectively. The proportion of L/L genotype was higher in cir-
rhotic patients without HCC than in CH group and the pro-
portion of P/P genotype was higher in CH group than in cir-
rhotic patients without HCC (P=0.008). 
Evaluation of the risk factors for the development of 
cirrhosis
In univariate analysis, the HBeAg positivity, detection rate
of HBV DNA, and distribution of genotype were significant-
ly different between both study groups. Therefore, multivari-
ate analysis for the risk factors of the development of cirrho-
sis was performed with the above three significant variables.
Multivariate logistic regression analysis revealed that detec-
Values are shown as mean±standard deviation or number.
*HBV DNA levels were measured by hybrid capture method (detection
limit >5×10
5 copies/mL).
ALT, alanine aminotransferase; HCC, hepatocellular carcinoma.
P
Age (yr) 59±75 9 ±7N S
Sex (Male/Female) 34/23 57/64 NS
ALT (U/L) 45±75 82±113 0.011
Albumin (g/dL) 4.1±0.3 3.1±0.7 <0.001
Total bilirubin (mg/dL) 0.9±0.6 3.0±4.8 <0.001
Platelet count (×10
3/mL) 224±48 110±75 <0.001
Prothrombin time (sec) 12.3±0.7 16.9±5.6 <0.001
Child-Pugh Class (A/B/C) 34/53/34
HCC 0 70
HBeAg (+/-) 16/41 47/62 0.055
HBV DNA (+/-)* 29/28 87/31 0.003
Table 1. Baseline characteristics of chronic hepatitis (CH) and
liver cirrhosis (LC) groups
Fig. 1. The results of single stranded conformational polymorphism
(SSCP) according to genotypes at codon 10 in transforming growth
factor (TGF)-b1 gene. There were 3 different patterns: 2 bands,
proline homozygous (P/P) genotype; 3 bands, proline/leucine het-
erozygous (P/L) genotype; and 1 band, leucine homozygous (L/L)
genotype. The size of amplified single DNA band was 170 bases.
The SSCP results were 100% concordant with the results of DNA
sequencing.
P/P L/L P/L
Fig. 2. The genotype distribution at codon 10 in chronic hepatitis
(CH) and liver cirrhosis (LC) groups. In the CH group, the propor-
tions of proline homozygous (P/P), proline/leucine heterozygous
(P/L), and leucine homozygous (L/L) genotypes were 32%, 51%,
and 17%, respectively. In the LC group, the proportions of P/P, P/L,
and L/L genotypes were 20%, 47%, and 33%, respectively. The
proportion of L/L genotype in LC group was higher than that in CH
group (P=0.017). 
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table HBV DNA and L/L genotype were the only risk fac-
tors for cirrhosis (Table 2). In comparing with undetectable
HBV DNA, the detectable HBV DNA showed an odds ratio
of 3.037 (95% confidence interval [CI]; 1.504 to 6.133, P=
0.002). In comparing with P/P genotype at codon 10, the L/L
genotype had an odds ratio of 3.408 (95% CI; 1.279 to 9.085,
P=0.014).
DISCUSSION
There are conflicting results in literature as to which geno-
type at codon 10 is associated with more production of TGF-
b1 or fibrosis than others. The L/L genotype was associated
with increased serum level of TGF-b1 and lung fibrosis (4).
However, other report suggested that the P/P genotype was
associated with increased serum level of TGF-b1 (11) and liver
fibrosis (8, 9). On the other hand, some reports found no asso-
ciation between genotype at codon 10 and liver fibrosis (5-7).
These contradictory results may be attributed to the hetero-
geneity of populations, races, diseases, and other confound-
ing factors. 
Present study indicated that patients with L/L genotype
at codon 10 in TGF-b1 had higher incidence of cirrhosis than
those with P/P genotype. In other words, patients with P/P
genotype at codon 10 had lower risk of progressing to cirrho-
sis than those with L/L genotype. This association was signifi-
cant after correcting for potential confounding variables (age,
sex, HBeAg, and HBV DNA) that might independently affect
the development of cirrhosis. 
In our previous report, we investigated the distribution of
genotype at codon 10 in 119 healthy controls that had not
HBsAg or anti-HCV. The proportions of P/P, P/L, and LL
genotypes were 26%, 45%, and 29%, respectively (12). The
proportion of P/P was similar to that of L/L genotype. In other
reports from Japan, China, and Korea about distribution of
genotype at codon 10 in general population, the proportion
of P/P was similar to that of L/L genotype (6, 9, 13). How-
ever, the P/P genotype was presented more frequently in CH
group than in healthy controls or LC group. In otherwise, L/L
genotype was presented more frequently in LC group than
in healthy controls or CH group. 
The production and activity of TGF-b1 are regulated by
complex posttranscriptional processes, including mRNA sta-
bilization, the assembly and activation of the latent TGF-b1
complex, and the modulation of receptor expression (14). The
genetic polymorphism at codon 10 presents within the sig-
nal sequence that is coding amino acids and conforms the pre-
pro-TGF-b1 with pro-TGF-b1 protein (15). Because most
of general genetic polymorphisms are located in the noncod-
ing regions of gene, it is very difficult to prove whether those
have direct impact on the phenotype of diseases (16). How-
ever, the genetic polymorphisms in coding region alter the
function or structure of encoded proteins. Those alterations
can directly influence the phenotype of diseases. Therefore we
assumed that the genetic polymorphism at codon 10 may
affect the production or activity of TGF-b1, because it pre-
sents within the coding region. 
The function of a signal sequence is translocation of newly
synthesized proteins across the membrane of the endoplas-
mic reticulum (17). It consists of three regions: a positively
charged NH2-terminal region, a central hydrophobic core,
and a polar COOH-terminal region (18). The amino acid
coded by codon 10 of TGF-b1 gene is located in the central
hydrophobic core and influences on the overall hydrophobic-
ity of core sequence (4). Therefore, the change of a neutral pro-
line to hydrophobic leucine residue disrupts the structure of
the region, alters transportation across endoplasmic reticulum
(4), and may affect the production or activity of TGF-b1. 
The serum TGF-b1 levels were not measured in present
study, because TGF-b1 is locally synthesized in the liver and
may not reach systemic circulation for measuring. In addi-
tion, because platelet is the main source of serum TGF-b1,
the serum levels of TGF-b1 do not always reflect its produc-
tion in liver (5). Therefore, the analysis of TGF-b1 mRNA
and protein expression in the liver are required for evaluat-
ing phenotypic differences according to the genetic polymor-
phisms.
TGF-b1 was also associated with the development of HCC
(19) and the L/L genotype at codon 10 in TGF-b1 was asso-
ciated with the development of HCC (7, 10). In the present
study, HCC was present in 58% of patients of LC group, and
the fact might influence on the results of this study. Howev-
er, 70-90% of the patients with HBsAg positive HCC had
already underlying cirrhosis (19). In addition, when cirrhot-
ic patients without HCC were selected for analysis, the L/L
genotype was still a significant risk factor for the development
of cirrhosis.
Liver fibrosis is a highly complex disease process in which
multiple genes interact with viral and environmental risk fac-
tors. Among them, age is a major risk factor for the develop-
ment of cirrhosis irrespective of any etiology. In order to ex-
clude the influence of age factor, present study’s inclusion cri-
teria restricted the age of patients over 50 yr old. The reasons
*HBV DNA levels were measured by hybrid capture method (detection
limit >5×10
5 copies/mL); 
� P/P, proline homozygous genotype; 
� P/L, pro-
line/leucine heterozygous genotype; 
�L/L, leucine homozygous geno-
type.
CI, confidence interval.
Odds ratio 95% CI P B Variables
HBV DNA (+)* 1.111 3.037 1.504-6.133 0.002
Genotypes
P/P
� 1
P/L
� 0.365 1.44 0.639-3.244 0.379
L/L
� 1.226 3.408 1.279-9.085 0.014
Table 2. Multivariate logistic regression analysis for the risk fac-
tors of cirrhosis568 S.K. Yu, O.S. Kwon, H.S. Jung, et al.
why present study chose 50 yr old for age were; first, cirrho-
sis was generally diagnosed around this age (20) and second,
it is not common that chronic HBV carriers remain chronic
hepatitis without cirrhosis over this age in Korean population
(personal experience). The longer duration of HBV infection
is also an important risk factor of cirrhosis. Because most Kore-
an patients with chronic HBV carriers were infected during
perinatal period or early childhood, we could assume that the
duration of HBV infection is nearly same as the patient’s age.
Present study showed no difference in the mean age of pati-
ents and in the duration of HBV infection between CH and
LC groups. 
Although initial HBV DNA levels were not known and
the levels of HBV DNA were not serially followed up, the
detectable HBV DNA was also a significant risk factor for
cirrhosis in chronic HBV carriers. The assay for HBV DNA
in the present study was the hybrid capture method, which
can detect the level of HBV DNA over than 105 copies/mL.
Comparing with real-time PCR method (lower detection
limit: 25-50 copies/mL) for detecting HBV DNA, hybrid
capture method is not sensitive enough to detect low level
of viremia less than 105 copies/mL. However, hybrid capture
method can detect the level of viremia that is considered as
the threshold for active disease state and needed to be treat-
ed by current hepatitis B treatment guidelines (21).
The rate of cirrhosis development was higher not only in
patients with continuous HBeAg-positive status compared
to those with HBeAg seroconversion but also in patients with
HBeAg reversion compared to those with sustained HBeAg
soroconversion (22). These results indicated that the HBeAg
was a strong risk factor for cirrhosis development. On the con-
trary of these reports, the annual incidence of cirrhosis was
higher in HBeAg-negative patients than in HBeAg-positive
patients (22). In Asian patients, cirrhosis and liver complica-
tions developed many years after HBeAg seroconversion (23).
These contradictory results were addressed by taking into
account both HBeAg status and HBV DNA level simulta-
neously in the evaluation of risk of cirrhosis development.
HBeAg seroconversion without decreasing HBV DNA level
was not a favorable marker for reducing fibrosis progression
in chronic HBV carriers (24). Therefore, the significance of
HBeAg as a risk factor for cirrhosis must be explained with
HBV DNA level. Furthermore, serum HBV DNA level over
104 copies/mL was associated with a significant risk for pro-
gression to cirrhosis independent of HBeAg status (25). Al-
though the present study did not analyze the risk of cirrho-
sis according to detail HBV DNA level, the level of HBV
DNA over 105 copies/mL rather than the HBeAg status was
more important in the development of cirrhosis. 
The present study had a limitation that chronic hepatitis
without cirrhosis was not diagnosed pathologically. We tried
to exclude cirrhosis by several clinical diagnostic tools. Chron-
ic hepatitis without cirrhosis was defined as no signs of the
radiologic and endoscopic evidence of cirrhosis and portal
hypertension. In addition to these criteria, patients with pla-
telet count less than 150,000/mL were excluded for ruling
out subclinical cirrhosis, because 1) low normal limit of pla-
telet count is 150,000/mL, 2) platelet count well reflects por-
tal hypertension (26) and 3) the degree of fibrosis is associ-
ated with platelet count in patients with chronic hepatitis B
(27). Almost all patients in CH group had aspartate amino-
transferase to platelet ratio index (APRI) less than 1.0 except
three patients (data not shown). Those three patients had APRI
over 1.0 and were all P/L genotype. Therefore they did not
influence the result of present study when proportions of P/P
and L/L genotypes were compared between CH and LC groups.
Although APRI is not a sensitive marker to diagnose cirrho-
sis, its value of less than 1.0 is excellent for excluding cirrho-
sis (28). However, there was still a possibility that some pati-
ents with subclinical cirrhosis were included in CH group.
The degree of cirrhosis in those patients might be mild com-
pared to patients in LC group.
Antiviral agents over 1 yr might influence to the progres-
sion of fibrosis or cirrhosis in chronic HBV carriers. Several
reports showed that antiviral agents prevented fibrosis pro-
gression pathologically in chronic HBV carriers (29) and im-
proved Child-Pugh score in patients with cirrhosis (30). There-
fore, present study did not assign the chronic HBV carriers
who were treated with antiviral agents over 1 yr to CH group.
In conclusion, the L/L genotype at codon 10 in TGF-b1
and detectable HBV DNA level over 105 copies/mL are risk
factors for development of liver cirrhosis. The genotyping at
codon 10 in TGF-b1 may be a useful screening tool for the
detection of the risk of cirrhosis development in chronic HBV
carriers. 
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